Keryx Biopharmaceuticals (NASDAQ:KERX) has been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $7.00.
Several analysts have commented on KERX shares. Zacks Investment Research cut shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 8th. ValuEngine cut shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. Finally, Stifel Nicolaus lowered their target price on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research note on Wednesday, November 8th.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Keryx Biopharmaceuticals by 5.1% during the 2nd quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock valued at $52,043,000 after buying an additional 349,521 shares during the period. Northern Trust Corp grew its stake in shares of Keryx Biopharmaceuticals by 6.9% during the 2nd quarter. Northern Trust Corp now owns 1,089,860 shares of the biopharmaceutical company’s stock valued at $7,881,000 after buying an additional 70,420 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Keryx Biopharmaceuticals by 1.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 973,229 shares of the biopharmaceutical company’s stock valued at $6,910,000 after buying an additional 10,175 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Keryx Biopharmaceuticals by 742.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 754,631 shares of the biopharmaceutical company’s stock valued at $5,358,000 after buying an additional 665,069 shares during the period. Finally, Monarch Partners Asset Management LLC grew its stake in shares of Keryx Biopharmaceuticals by 62.0% during the 3rd quarter. Monarch Partners Asset Management LLC now owns 685,700 shares of the biopharmaceutical company’s stock valued at $4,868,000 after buying an additional 262,540 shares during the period. 64.82% of the stock is owned by institutional investors.
Keryx Biopharmaceuticals (KERX) traded up $0.01 during mid-day trading on Tuesday, reaching $4.71. 802,872 shares of the company’s stock traded hands, compared to its average volume of 1,233,800. The stock has a market cap of $561.69, a PE ratio of -3.14 and a beta of 4.92. The company has a debt-to-equity ratio of 13.95, a current ratio of 4.46 and a quick ratio of 3.76. Keryx Biopharmaceuticals has a 12-month low of $4.33 and a 12-month high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.03). The firm had revenue of $15.00 million during the quarter, compared to analysts’ expectations of $18.88 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The firm’s revenue was up 138.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.39) earnings per share. equities analysts anticipate that Keryx Biopharmaceuticals will post -1.36 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Brokerages Set Keryx Biopharmaceuticals (KERX) PT at $7.00” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://transcriptdaily.com/2018/01/05/brokerages-set-keryx-biopharmaceuticals-kerx-pt-at-7-00.html.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.